An immunoproteomic approach to characterize the CAR interactome and signalosome
Ontology highlight
ABSTRACT: Adoptive transfer of chimeric antigen receptor (CAR)-T cells is expected to become the first line of treatment for multiple malignancies, following the enormous success of anti-CD19 therapies. However, their mechanism of action is not fully understood, and clear guidelines for the design of safe and efficient receptors are missing. We hereby describe a systematic analysis of the CAR “signalosome” in human primary T cells. Two CAR designs were compared: a second-generation (PSCA2) and a third-generation (PSCA3) anti-PSCA CAR. Phosphorylation events triggered by CAR-mediated recognition of target cells were quantified by mass spectrometry.
INSTRUMENT(S):
ORGANISM(S): Homo Sapiens (human)
TISSUE(S): T Cell, T-lymphocyte
DISEASE(S): Pancreatic Cancer
SUBMITTER: 
John Koomen
LAB HEAD: Daniel Abate-Daga
PROVIDER: PXD007086 | Pride | 2019-11-07
REPOSITORIES: Pride
ACCESS DATA
